• News

CPhI Annual Report 2019

‘FDA should withdraw ANDAs’, and ‘new technologies could bring massive improvements in efficiency’ if implemented correctly. Pharma 4.0 will bring…

• Launch

Dr. Reddy’s Laboratories announces the launch of Fosaprepitant for Injection in the U.S. Market

Hyderabad, September 14, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

• Market
• New Launches

Dr. Reddy’s Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR)in the U.S. Market

Hyderabad, September 07, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

• New Launches

Dr. Reddy’s Laboratories announces the launch of Pregabalin Capsules in the U.S. Market

Hyderabad, July 30, 2019:, Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

• Latest

Syngene announces Q1 FY20 results

Revenue up 4% to Rs. 441 Cr, Profit After Tax increases 9% to 72 Cr; Dr. Mahesh Bhalgat appointed Chief…

• New Launches
• US FDA Approval

Dr. Reddy’s announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market

Hyderabad, July 22, 2019: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

• New Launches

Dr. Reddy’s announces the launch of the over-the-counter store brand equivalent of Mucinex® D Extended Release Tablets in two strengths in the U.S. Market

Hyderabad, July 09, 2019: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to…

• New Launches

Dr. Reddy’s Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL)Single-dose Vial in the U.S. Market

Hyderabad, July 04, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

• Approval
• US FDA Approval

Lupin’s Pithampur Unit-3 (Indore) receives EIR from USFDA

Mumbai, April 18, 2019: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) for its…

Gujarat Based Espee Group gets USFDA Approval for their Manufacturing Plant in USA

New Delhi, February 28, 2019: Aavis Pharmaceuticals, part of Espee Group, located in Hoschton, GA, completed an inspection by the US Food…